2024-01-26 02:41:50 ET
Summary
- Carl Zeiss Meditec has seen a significant increase in stock performance, up over 29% in less than 3 months.
- The company has shown strong top-line growth but a decline in EBIT and EBIT margin.
- Challenges include a decline in volume, unfavorable sales mix, and increased R&D spending. However, I view the company to still be a "BUY" here, even if one with lower appeal.
Dear readers/followers,
Carl Zeiss Meditec (CZMWF) is a company that I've reviewed a few times, going from an overall "HOLD" rating to a "BUY" rating when the company dropped down to an undervalued price. I actually bought a non-trivial position at the time of my last position - and this has not only outperformed but outperformed significantly. By significantly, in this context, I mean that the company is up over 29% in less than 3 months, which goes into the category of market-beating performance.
It once again shows the importance of investing at the right valuation, and why, with my strategy, I seem to have a decent chance of outperforming the overall market if I focus on qualitative undervalued investments....
Read the full article on Seeking Alpha
For further details see:
Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential